Skip to main content

Table 2 Clinical course of patients with pulmonary metastases from PDAC who received pulmonary resection

From: Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study

Case

Age/Sex

PDAC surgery

pStage

Adjuvant chemotherapy

RFS (Months)

PM location (tumour number)

Neoadjuvant chemotherapy

PM surgery

2nd adjuvant chemotherapy

RFS (PM surgery) (months)

2nd recurrence site

2nd recurrence treatment

OS (Months)

1

72M

PPPD + PVR

2B

-

36

Left upper lobe (1)

Left lower lobe (1)

Partial resection

98

132 (Alive)

2

66F

SSPPD

3

S-1

47

Right upper lobe (1)

Right lower lobe (2)

Partial resection

13

60 (Alive)

3

68M

SSPPD + PVR

3

S-1

24

Right upper lobe (1)

Left upper lobe (1)

Partial resection

3

Right pulmonary

metastases

GEM + nab-PTX

 → FFX

55 (Alive)

4

70M

SSPPD + PVR

2B

S-1

13

Left lower lobe (2)

Partial resection

3

Right pulmonary

metastases

GEM + nab-PTX

32 (Alive)

5

71M

DP

3

S-1

31

Right upper lobe (1)

Right Lower lobe (1)

GEM + nab-PTX

Partial resection

GEM + nab-PTX

 → GEM

9

53 (Alive)

6

80M

DP

1A

S-1

36

Right upper lobe (1)

Left upper lobe (1)

GEM + nab-PTX

Partial resection

3

59 (Alive)

  1. PPPD pylorus-preserving pancreaticoduodenectomy, SSPPD subtotal stomach preserving pancreaticoduodenectomy, DP distal pancreatectomy, PVR portal vein resection, PM pulmonary metastasis, GEM gemcitabine, nab-PTX nab-paclitaxel, FFX FOLFIRINOX, RFS recurrence-free survival